Christian L. Althaus

Christian L. Althaus

Computational epidemiologist

Publications

Updated: 5 Dec 2023

  1. Peer-reviewed publications
  2. Contribution to books
  3. Other (non peer-reviewed publications, preprints, reports)

You can find the Relative Citation Ratios (RCR) on iCite and a complete list of publications and preprints on PubMed or Google Scholar.

1. Peer-reviewed publications

  1. Reflections On Epidemiological Modeling To Inform Policy During The COVID-19 Pandemic In Western Europe, 2020-23. Jit M, Ainslie K, Althaus C, Caetano C, Colizza V, Paolotti D, Beutels P, Willem L, Edmunds J, Nunes B, Namorado S, Faes C, Low N, Wallinga J, Hens N. Health Aff (Millwood). 2023 Dec;42(12):1630-1636.
  2. Socio-demographic characteristics associated with COVID-19 vaccination uptake in Switzerland: longitudinal analysis of the CoMix study. Reichmuth ML, Heron L, Riou J, Moser A, Hauser A, Low N, Althaus CL. BMC Public Health. 2023 Aug 10;23(1):1523.
  3. Importation of Alpha and Delta variants during the SARS-CoV-2 epidemic in Switzerland: Phylogenetic analysis and intervention scenarios. Reichmuth ML, Hodcroft EB, Althaus CL. PLoS Pathog. 2023 Aug 10;19(8):e1011553.
  4. Social contact patterns during the COVID-19 pandemic in 21 European countries - evidence from a two-year study. Wong KLM, Gimma A, Coletti P; CoMix Europe Working Group; Faes C, Beutels P, Hens N, Jaeger VK, Karch A, Johnson H, Edmunds W, Jarvis CI. BMC Infect Dis. 2023 Apr 26;23(1):268.
  5. Projecting the development of antimicrobial resistance in Neisseria gonorrhoeae from antimicrobial surveillance data: a mathematical modelling study. Riou J, Althaus CL, Allen H, Cole MJ, Grad YH, Heijne JCM, Unemo M, Low N. BMC Infect Dis. 2023 Apr 20;23(1):252.
  6. Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region. Emmenegger M, De Cecco E, Lamparter D, Jacquat RPB, Riou J, Menges D, Ballouz T, Ebner D, Schneider MM, Morales IC, Doğançay B, Guo J, Wiedmer A, Domange J, Imeri M, Moos R, Zografou C, Batkitar L, Madrigal L, Schneider D, Trevisan C, Gonzalez-Guerra A, Carrella A, Dubach IL, Xu CK, Meisl G, Kosmoliaptsis V, Malinauskas T, Burgess-Brown N, Owens R, Hatch S, Mongkolsapaya J, Screaton GR, Schubert K, Huck JD, Liu F, Pojer F, Lau K, Hacker D, Probst-Müller E, Cervia C, Nilsson J, Boyman O, Saleh L, Spanaus K, von Eckardstein A, Schaer DJ, Ban N, Tsai CJ, Marino J, Schertler GFX, Ebert N, Thiel V, Gottschalk J, Frey BM, Reimann RR, Hornemann S, Ring AM, Knowles TPJ, Puhan MA, Althaus CL, Xenarios I, Stuart DI, Aguzzi A. iScience. 2023 Feb 17;26(2):105928.
  7. Direct and indirect effects of the COVID-19 pandemic on mortality in Switzerland. Riou J, Hauser A, Fesser A, Althaus CL, Egger M, Konstantinoudis G. Nat Commun. 2023 Jan 6;14(1):90.
  8. Impact of cross-border-associated cases on the SARS-CoV-2 epidemic in Switzerland during summer 2020 and 2021. Reichmuth ML, Hodcroft EB, Riou J, Neher RA, Hens N, Althaus CL. Epidemics. 2022 Dec;41:100654.
  9. EpiLPS: A fast and flexible Bayesian tool for estimation of the time-varying reproduction number. Gressani O, Wallinga J, Althaus CL, Hens N, Faes C. PLoS Comput Biol. 2022 Oct 10;18(10):e1010618.
  10. Pregnancy during COVID-19: social contact patterns and vaccine coverage of pregnant women from CoMix in 19 European countries. Wong KLM, Gimma A, Paixao ES; CoMix Europe Working Group, Faes C, Beutels P, Hens N, Jarvis CI, Edmunds WJ. BMC Pregnancy Childbirth. 2022 Oct 8;22(1):757.
  11. Accelerated partner therapy contact tracing for people with chlamydia (LUSTRUM): a crossover cluster-randomised controlled trial. Estcourt CS, Stirrup O, Copas A, Low N, Mapp F, Saunders J, Mercer CH, Flowers P, Roberts T, Howarth AR, Owusu MW, Symonds M, Nandwani R, Ogwulu C, Brice S, Johnson AM, Althaus CL, Williams E, Comer-Schwartz A, Tostevin A, Cassell JA. Lancet Public Health. 2022 Oct;7(10):e853-e865.
  12. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, Subramoney K, Makatini Z, Moyo S, Amoako DG, Baxter C, Althaus CL, Anyaneji UJ, Kekana D, Viana R, Giandhari J, Lessells RJ, Maponga T, Maruapula D, Choga W, Matshaba M, Mbulawa MB, Msomi N; NGS-SA consortium, Naidoo Y, Pillay S, Sanko TJ, San JE, Scott L, Singh L, Magini NA, Smith-Lawrence P, Stevens W, Dor G, Tshiabuila D, Wolter N, Preiser W, Treurnicht FK, Venter M, Chiloane G, McIntyre C, O'Toole A, Ruis C, Peacock TP, Roemer C, Pond SLK, Williamson C, Pybus OG, Bhiman JN, Glass A, Martin DP, Jackson B, Rambaut A, Laguda-Akingba O, Gaseitsiwe S, von Gottberg A, de Oliveira T. Nat Med. 2022 Sep;28(9):1785-1790.
  13. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland. Anderegg N, Althaus CL, Colin S, Hauser A, Laube A, Mäusezahl M, Wagner M, Zaffora B, Riou J. Swiss Med Wkly. 2022 Apr 19;152:w30163.
  14. Replacement of the Gamma by the Delta variant in Brazil: Impact of lineage displacement on the ongoing pandemic.. Giovanetti M, Fonseca V, Wilkinson E, Tegally H, San EJ, Althaus CL, Xavier J, Nanev Slavov S, Viala VL, Ranieri Jerônimo Lima A, Ribeiro G, Souza-Neto JA, Fukumasu H, Lehmann Coutinho L, Venancio da Cunha R, Freitas C, Campelo de A E Melo CF, Navegantes de Araújo W, Do Carmo Said RF, Almiron M, de Oliveira T, Coccuzzo Sampaio S, Elias MC, Covas DT, Holmes EC, Lourenço J, Kashima S, de Alcantara LCJ. Virus Evol. 2022 Mar 18;8(1):veac024.
  15. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ, Bester PA, Boni MF, Chand M, Choga WT, Colquhoun R, Davids M, Deforche K, Doolabh D, du Plessis L, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M, Hardie D, Hill V, Hsiao NY, Iranzadeh A, Ismail A, Joseph C, Joseph R, Koopile L, Kosakovsky Pond SL, Kraemer MUG, Kuate-Lere L, Laguda-Akingba O, Lesetedi-Mafoko O, Lessells RJ, Lockman S, Lucaci AG, Maharaj A, Mahlangu B, Maponga T, Mahlakwane K, Makatini Z, Marais G, Maruapula D, Masupu K, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Mendes A, Mlisana K, Mnguni A, Mohale T, Moir M, Moruisi K, Mosepele M, Motsatsi G, Motswaledi MS, Mphoyakgosi T, Msomi N, Mwangi PN, Naidoo Y, Ntuli N, Nyaga M, Olubayo L, Pillay S, Radibe B, Ramphal Y, Ramphal U, San JE, Scott L, Shapiro R, Singh L, Smith-Lawrence P, Stevens W, Strydom A, Subramoney K, Tebeila N, Tshiabuila D, Tsui J, van Wyk S, Weaver S, Wibmer CK, Wilkinson E, Wolter N, Zarebski AE, Zuze B, Goedhals D, Preiser W, Treurnicht F, Venter M, Williamson C, Pybus OG, Bhiman J, Glass A, Martin DP, Rambaut A, Gaseitsiwe S, von Gottberg A, de Oliveira T. Nature. 2022 Mar;603(7902):679-686.
  16. The epidemic volatility index, a novel early warning tool for identifying new waves in an epidemic. Kostoulas P, Meletis E, Pateras K, Eusebi P, Kostoulas T, Furuya-Kanamori L, Speybroeck N, Denwood M, Doi SAR, Althaus CL, Kirkeby C, Rohani P, Dhand NK, Peñalvo JL, Thabane L, BenMiled S, Sharifi H, Walter SD. Sci Rep. 2021 Dec 10;11(1):23775.
  17. Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. Chen C, Nadeau SA, Topolsky I, Manceau M, Huisman JS, Jablonski KP, Fuhrmann L, Dreifuss D, Jahn K, Beckmann C, Redondo M, Noppen C, Risch L, Risch M, Wohlwend N, Kas S, Bodmer T, Roloff T, Stange M, Egli A, Eckerle I, Kaiser L, Denes R, Feldkamp M, Nissen I, Santacroce N, Burcklen E, Aquino C, de Gouvea AC, Moccia MD, Grüter S, Sykes T, Opitz L, White G, Neff L, Popovic D, Patrignani A, Tracy J, Schlapbach R, Dermitzakis ET, Harshman K, Xenarios I, Pegeot H, Cerutti L, Penet D, Blin A, Elies M, Althaus CL, Beisel C, Beerenwinkel N, Ackermann M, Stadler T. Epidemics. 2021 Dec;37:100480.
  18. Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study. Riou J, Dupont C, Bertagnolio S, Gupta RK, Kouyos RD, Egger M, L Althaus C. BMC Infect Dis. 2021 Oct 7;21(1):1042.
  19. Socioeconomic position and the COVID-19 care cascade from testing to mortality in Switzerland: a population-based analysis. Riou J, Panczak R, Althaus CL, Junker C, Perisa D, Schneider K, Criscuolo NG, Low N, Egger M. Lancet Public Health. 2021 Jul 9:S2468-2667(21)00160-2.
  20. Quantifying superspreading for COVID-19 using Poisson mixture distributions. Kremer C, Torneri A, Boesmans S, Meuwissen H, Verdonschot S, Vanden Driessche K, Althaus CL, Faes C, Hens N. Sci Rep. 2021 Jul 8;11(1):14107.
  21. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, Reichmuth ML, Bowen JE, Walls AC, Corti D, Bloom JD, Veesler D, Mateo D, Hernando A, Comas I, González-Candelas F; SeqCOVID-SPAIN consortium, Stadler T, Neher RA. Nature. 2021 Jul;595(7869):707-712.
  22. A Data-Driven Simulation of the Exposure Notification Cascade for Digital Contact Tracing of SARS-CoV-2 in Zurich, Switzerland. Menges D, Aschmann HE, Moser A, Althaus CL, von Wyl V. JAMA Netw Open. 2021 Apr 1;4(4):e218184.
  23. Early evidence of effectiveness of digital contact tracing for SARS-CoV-2 in Switzerland. Salathé M, Althaus C, Anderegg N, Antonioli D, Ballouz T, Bugnon E, Čapkun S, Jackson D, Kim SI, Larus J, Low N, Lueks W, Menges D, Moullet C, Payer M, Riou J, Stadler T, Troncoso C, Vayena E, von Wyl V. Swiss Med Wkly. 2020 Dec 16;150:w20457.
  24. The approximately universal shapes of epidemic curves in the Susceptible-Exposed-Infectious-Recovered (SEIR) model. Heng K, Althaus CL. Sci Rep. 2020 Nov 9;10(1):19365.
  25. COVID-19 infectivity profile correction. Ashcroft P, Huisman JS, Lehtinen S, Bouman JA, Althaus CL, Regoes RR, Bonhoeffer S.J. Swiss Med Wkly. 2020 Aug 5;150:w20336.
  26. Estimation of SARS-CoV-2 mortality during the early stages of an epidemic: A modeling study in Hubei, China, and six regions in Europe. Hauser A, Counotte MJ, Margossian CC, Konstantinoudis G, Low N, Althaus CL, Riou J. PLoS Med. 2020 Jul 28;17(7):e1003189.
  27. Dynamic interventions to control COVID-19 pandemic: a multivariate prediction modelling study comparing 16 worldwide countries. Chowdhury R, Heng K, Shawon MSR, Goh G, Okonofua D, Ochoa-Rosales C, Gonzalez-Jaramillo V, Bhuiya A, Reidpath D, Prathapan S, Shahzad S, Althaus CL, Gonzalez-Jaramillo N, Franco OH; Global Dynamic Interventions Strategies for COVID-19 Collaborative Group. Eur J Epidemiol. 2020 May;35(5):389-399.
  28. Understanding the spread of de novo and transmitted macrolide-resistance in Mycoplasma genitalium. Cadosch D, Garcia V, Jensen JS, Low N, Althaus CL. PeerJ. 2020 Apr 7;8:e8913.
  29. Accelerated partner therapy (APT) partner notification for people with Chlamydia trachomatis: protocol for the Limiting Undetected Sexually Transmitted infections to RedUce Morbidity (LUSTRUM) APT cross-over cluster randomised controlled trial. Estcourt CS, Howarth AR, Copas A, Low N, Mapp F, Woode Owusu M, Flowers P, Roberts T, Mercer CH, Wayal S, Symonds M, Nandwani R, Saunders J, Johnson AM, Pothoulaki M, Althaus C, Pickering K, McKinnon T, Brice S, Comer A, Tostevin A, Ogwulu CD, Vojt G, Cassell JA. BMJ Open. 2020 Mar 29;10(3):e034806.
  30. Gini coefficients for measuring the distribution of sexually transmitted infections among individuals with different levels of sexual activity. Gsteiger S, Low N, Sonnenberg P, Mercer CH, Althaus CL. PeerJ. 2020 Jan 20;8:e8434.
  31. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Riou J, Althaus CL. Euro Surveill. 2020 Jan;25(4):2000058.
  32. Transmission of and susceptibility to seasonal influenza in Switzerland from 2003 to 2015. Brugger J, Althaus CL. Epidemics. 2020 Mar;30:100373.
  33. Rise and fall of the new variant of Chlamydia trachomatis in Sweden: mathematical modelling study. Smid JH, Althaus CL, Low N, Unemo M, Herrmann B. Sex Transm Infect. 2020 Aug;96(5):375-379.
  34. Impact of age-specific immunity on the timing and burden of the next Zika virus outbreak. Counotte MJ, Althaus CL, Low N, Riou J. PLoS Negl Trop Dis. 2019 Dec 26;13(12):e0007978.
  35. Discrepancies between observed data and predictions from mathematical modelling of the impact of screening interventions on Chlamydia trachomatis prevalence. Smid J, Althaus CL, Low N. Sci Rep. 2019 May 17;9(1):7547.
  36. The use of mathematical modelling studies for evidence synthesis and guideline development: a glossary. Porgo TV, Norris SL, Salanti G, Johnson LF, Simpson JA, Low N, Egger M, Althaus CL. Res Synth Methods. 2019 Mar;10(1):125-133.
  37. Does infection with Chlamydia trachomatis induce long-lasting partial immunity? Insights from mathematical modelling. Omori R, Chemaitelly H, Althaus CL, Abu-Raddad LJ. Sex Transm Infect. 2019 Mar;95(2):115-121.
  38. Exploring variation in human papillomavirus vaccination uptake in Switzerland: a multilevel spatial analysis of a national vaccination coverage survey. Riesen M, Konstantinoudis G, Lang P, Low N, Hatz C, Maeusezahl M, Spaar A, Bühlmann M, Spycher BD, Althaus CL. BMJ Open. 2018 May 17;8(5):e021006.
  39. Age difference between heterosexual partners in Britain: implications for the spread of Chlamydia trachomatis. Smid J, Garcia V, Low N, Mercer CH, Althaus CL. Epidemics. 2018 Mar 31. pii: S1755-4365(17)30149-4.
  40. Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Riesen M, Garcia V, Low N, Althaus CL. Vaccine. 2017 Dec 19;35(52):7312-7321.
  41. Developing WHO guidelines: Time to formally include evidence from mathematical modelling studies. Egger M, Johnson L, Althaus C, Schöni A, Salanti G, Low N, Norris SL. F1000Res. 2017 Aug 29;6:1584.
  42. Detection of antibiotic resistance is essential for gonorrhoea point-of-care testing: a mathematical modelling study. Fingerhuth SM, Low N, Bonhoeffer S, Althaus CL. BMC Med. 2017 Jul 26;15(1):142.
  43. A new rapid resazurin-based microdilution assay for antimicrobial susceptibility testing of Neisseria gonorrhoeae. Foerster S, Desilvestro V, Hathaway LJ, Althaus CL, Unemo M. J Antimicrob Chemother. 2017 Jul 1;72(7):1961-1968.
  44. Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae. Foerster S, Unemo M, Hathaway LJ, Low N, Althaus CL. BMC Microbiol. 2016 Sep 17;16(1):216.
  45. Heterogeneity in district-level transmission of Ebola virus disease during the 2013-2015 epidemic in West Africa. Krauer F, Gsteiger S, Low N, Hansen CH, Althaus CL. PLOS Negl Trop Dis. 2016 Jul;10(7): e0004867.
  46. Antibiotic-resistant Neisseria gonorrhoeae spread faster with more treatment, not more sexual partners. Fingerhuth SM, Bonhoeffer S, Low N, Althaus CL. PLOS Pathog. 2016 May;12(5): e1005611.
  47. Potential impact of sexual transmission on Ebola virus epidemiology: Sierra Leone as a case study. Abbate JL, Murall CL, Richner H, Althaus CL. PLOS Negl Trop Dis. 2016 May;10(5): e0004676.
  48. Genetic resistance determinants, in vitro time-kill curve analysis and pharmacodynamic functions for the novel topoisomerase II inhibitor ETX0914 (AZD0914) in Neisseria gonorrhoeae. Foerster S, Golparian D, Jacobsson S, Hathaway LJ, Low N, Shafer WM, Althaus CL, Unemo M. Front Microbiol. 2015;6:1377.
  49. Rapid drop in the reproduction number during the Ebola outbreak in the Democratic Republic of Congo. Althaus CL. PeerJ. 2015 Nov 19;3:e1418.
  50. Measles vaccination coverage and cases among vaccinated persons. Althaus CL, Salathé M. Emerg Infect Dis. 2015 Aug;21(8):1480-1481.
  51. The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission. Kucharski AJ, Althaus CL. Euro Surveill. 2015;20(25):pii=21167(25).
  52. Ebola virus disease outbreak in Nigeria: Transmission dynamics and rapid control. Althaus CL, Low N, Musa EO, Shuaib F, Gsteiger S. Epidemics. 2015 Jun;11:80-4.
  53. Ebola superspreading. Althaus CL. Lancet Infect Dis. 2015 May;15(5):507-8.
  54. Of mice, macaques and men: scaling of virus dynamics and immune responses. Althaus CL. Front Microbiol. 2015 Apr 23;6:355.
  55. Quantifying the turnover of transcriptional subclasses of HIV-1-infected cells. Althaus CL, Joos B, Perelson AS, Günthard HF. PLOS Comput Biol. 2014 Oct;10(10): e1003871.
  56. Estimating the reproduction number of Ebola virus (EVOB) during the 2014 outbreak in West Africa. Althaus CL. PLOS Curr. 2014 Sep 2;6.
  57. Reinfection by untreated partners of people treated for Chlamydia trachomatis and Neisseria gonorrhoeae: mathematical modelling study. Low N, Heijne JC, Herzog SA, Althaus CL. Sex Transm Infect. 2014 May;90(3):254-6.
  58. Effectiveness and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections: observational study, systematic reviews and mathematical modelling. Althaus CL, Turner KM, Mercer CH, Auguste P, Roberts TE, Bell G, Herzog SA, Cassell JA, Edmunds WJ, White PJ, Ward H, Low N. Health Technol Assess. 2014 Jan;18(2):1-100.
  59. Direct and indirect effects of screening for Chlamydia trachomatis on the prevention of pelvic inflammatory disease: mathematical modeling study. Herzog SA, Heijne JC, Scott P, Althaus CL, Low N. Epidemiology. 2013 Nov;24(6):854-62.
  60. Case and partnership reproduction numbers for a curable sexually transmitted infection. Heijne JC, Herzog SA, Althaus CL, Low N, Kretzschmar M. J Theor Biol. 2013 Aug 21;331:38-47.
  61. Insights into the timing of repeated testing after treatment for Chlamydia trachomatis: data and modelling study. Heijne JC, Herzog SA, Althaus CL, Tao G, Kent C, Low N. Sex Transm Infect. 2013 Feb;89(1):57-62.
  62. Individual and population level effects of partner notification for Chlamydia trachomatis. Althaus CL, Heijne JC, Herzog SA, Roellin A, Low N. PLoS One. 2012;7(12):e51438.
  63. Timing of progression from Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study. Herzog SA, Althaus CL, Heijne JC, Oakeshott P, Kerry S, Hay P, Low N. BMC Infect Dis. 2012 Aug 11;12(1):187.
  64. Describing the Progression From Chlamydia trachomatis and Neisseria gonorrhoeae to Pelvic Inflammatory Disease: Systematic Review of Mathematical Modeling Studies. Herzog SA, Heijne JC, Althaus CL, Low N. Sex Transm Dis. 2012 Aug;39(8):628-37.
  65. Towards more robust estimates of the transmissibility of Chlamydia trachomatis. Althaus CL, Heijne JC, Low N. Sex Transm Dis. 2012 May;39(5):402-4.
  66. Impaired immune evasion in HIV through intracellular delays and multiple infection of cells. Althaus CL, De Boer RJ. Proc Biol Sci. 2012 Aug 7;279(1740):3003-10.
  67. Transmission of Chlamydia trachomatis through sexual partnerships: a comparison between three individual-based models and empirical data. Althaus CL, Turner KM, Schmid BV, Heijne JC, Kretzschmar M, Low N. J R Soc Interface. 2012 Jan 7;9(66):136-46.
  68. Implications of CTL-mediated killing of HIV-infected cells during the non-productive stage of infection. Althaus CL, De Boer RJ. PLoS One. 2011 Feb 7;6(2):e16468.
  69. The role of re-infection and partner notification in the efficacy of chlamydia screening programmes. Heijne JCM, Althaus CL, Herzog SA, Kretzschmar M, Low N. J Infect Dis. 2011 Feb 1;203(3):372-7.
  70. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Althaus CL, Heijne JCM, Roellin A, Low N. Epidemics. 2010 Sep;2(3):123-31.
  71. Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy. Althaus CL, De Boer RJ. Mol Syst Biol. 2010; 6:348.
  72. Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling: life span of infected cells, viral generation time, and basic reproductive number, R0. Althaus CL, De Vos AS, De Boer RJ. J Virol. 2009 Aug;83(15):7659-67.
  73. Dynamics of immune escape during HIV/SIV infection. Althaus CL, De Boer RJ. PLoS Comput Biol. 2008 Jul 18;4(7):e1000103.
  74. Dynamics of CD8+ T cell responses during acute and chronic lymphocytic choriomeningitis virus infection. Althaus CL, Ganusov VV, De Boer RJ. J Immunol. 2007 Sep 1;179(5):2944-51.
  75. Stochastic or deterministic: what is the effective population size of HIV? Kouyos RD, Althaus CL, Bonhoeffer S. Trends Microbiol. 2006 Dec;14(12):507-11.
  76. Stochastic interplay between mutation and recombination during the acquisition of drug resistance mutations in human immunodeficiency virus type 1. Althaus CL, Bonhoeffer S. J Virol. 2005 Nov;79(21):13572-8.
  77. Recombination in HIV and the evolution of drug resistance: for better or for worse? Bretscher MT, Althaus CL, Müller V, Bonhoeffer S. Bioessays. 2004 Feb; 26(2): 180-8.

2. Contribution to books

  1. Modeling the Ebola epidemic: challenges and lessons for the future. Althaus CL. In Evans NG, Smith TC, Majumder MS (Eds.), Ebola’s Message: Public Health and Medicine in the Twenty-First Century. MIT Press, 2016.

3. Other (non peer-reviewed publications, preprints, reports)

  1. Social contacts and attitudes towards vaccination during the COVID-19 pandemic: Insights from the CoMix study. Reichmuth M, Heron L, Low N, Althaus CL. University of Bern, Institute of Social and Preventive Medicine. 2022.
  2. Prüfung des Eskalationsmodells (Art. 6 und 7 EpG) unter besonderer Berücksichtigung der Epidemiologie übertragbarer Krankheiten sowie Public-Health-Aspekten: Thesenpapier im Auftrag des Bundesamtes für Gesundheit (BAG) im Rahmen der Revision des Epidemiengesetzes (EpG). Althaus CL, Schlaufer C, Frahsa A, Hadorn S, Sager F, Zwahlen M. University of Bern, Multidisciplinary Center for Infectious Diseases. 2022.
  3. A public health strategy for SARS-CoV-2, grounded in science, should guide Swiss schools through the coming winter. Keiser O, Agoritsas T, Althaus CL, Azman AS, de Quervain D, Flahault A, Goutaki M, Merglen A, Eckerle I. Swiss Med Wkly. 2021 Oct 14;151:w30086.
  4. COVID-19 epidemic in Switzerland: on the importance of testing, contact tracing and isolation. Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, Zwahlen M, Senti G, Battegay M, Wilder-Smith A, Eckerle I, Egger M, Low N. Swiss Med Wkly. 2020 Mar 19;150:w20225.
  5. Fitness cost and benefit of antimicrobial resistance in Neisseria gonorrhoeae: Multidisciplinary approaches are needed. Unemo M, Althaus CL. PLoS Med. 2017 Oct 31;14(10):e1002423.
  6. How relevant is sexual transmission of Zika virus? Althaus CL, Low N. PLOS Med. 2016 Oct;13(10):e1002157.
  7. How sex acts scale with the number of sex partners: evidence from Chlamydia trachomatis data and implications for control. Althaus CL, Choisy M, Alizon S, the CSF group. PeerJ PrePrints. 2015;3:e940v2